Equity Profile
Pre-Earnings Brief
Waters Corporation (WAT) operates in the health care sector, specifically within life sciences tools and services. The company is known for its analytical instruments and software, which are crucial for laboratories in pharmaceuticals, biotechnology, and environmental testing....
EPS
Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products and services.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+3.56%
Avg Stock Reaction
+0.84%
In the last quarter, Waters reported an EPS of $4.53, slightly beating estimates. However, the stock experienced a significant drop of nearly 14% the following day, indicating market concerns despite the positive earnings surprise.
Management Promises & Guidance
Analysts expect Waters to report solid earnings this quarter, with a consensus EPS of $2.31. Investors are keen to see if the company can maintain its strong performance amidst market fluctuations.
Bull Case
If Waters exceeds EPS estimates and shows strong revenue growth, it could signal robust demand for its products, leading to a positive market reaction.
Bear Case
Conversely, if the company fails to meet expectations or provides weak guidance, it may face significant downward pressure on its stock price.
EPS
2.31Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
1.2BRevenue figures provide insight into the company's sales performance and market demand for its products and services.
Expectations
The print will turn on these two things.
Q1
Will Waters achieve an EPS of $2.31 or better?
This specific EPS target is crucial as it reflects the company's ability to manage costs and generate profit, which will heavily influence investor sentiment.
Q2
What insights can management provide about revenue growth trends?
Understanding revenue growth will help gauge market demand for Waters' products and services, which is vital for future performance.
Edge
Why consensus could be wrong
The Street may be underestimating the impact of recent product innovations on revenue growth, which could drive better-than-expected results.
Supporting Evidence
Waters has a strong track record of beating EPS estimates, suggesting potential for another positive surprise.
The recent drop in stock price may have created a buying opportunity, as the fundamentals remain strong.
Market demand for life sciences tools is increasing, which could lead to higher revenue than anticipated.
Key Risk
If the revenue growth significantly exceeds expectations, it could challenge the current consensus outlook.
Edge
Pre-commit to what would confirm each case.
The market is closely watching these earnings as they will provide insights into Waters' operational efficiency and market demand.
Bull Confirmed If
An EPS of $2.35 or higher, coupled with strong revenue growth, would confirm a bullish outlook.
Bear Confirmed If
An EPS below $2.27 would indicate potential weaknesses in the company's performance.
Pre-Earnings Positioning
Implied Move
±4.2%
Historical Avg
±6.8%
The options market is pricing in a potential move of around 4.2%, indicating some uncertainty about the earnings report.
Options are pricing ±6.5% while WAT has averaged ±6.8% over the last 8 prints — setup is roughly in line with history.
30d HV
32.8%
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Waters beats expectations, history suggests the stock could rise by around 0.84%, confirming strong operational performance.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.
Miss
A miss could lead to a significant downturn, with historical data suggesting an average drop of around 6.84% following disappointing results.
Preparation
House & Senate STOCK Act disclosures over the trailing 6 months.
Trades
6
2 buys·2 sells
Members
5
House only
Est. Notional
$6,006.00–$90,000.00
disclosed dollar ranges
Most Active Members
2 trades
Net selling
1 trade
Net buying
1 trade
Net buying
0 trades
Mixed
Recent Transactions
Traded Mar 18, 2026 · disclosed Apr 7, 2026
$1,001.00–$15,000.00
Traded Mar 10, 2026 · disclosed Apr 13, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
LOEWS CORP
Traded Feb 13, 2026 · disclosed Mar 18, 2026
$1,001.00–$15,000.00
Traded Feb 10, 2026 · disclosed Feb 23, 2026
$1,001.00–$15,000.00
Traded Feb 9, 2026 · disclosed Mar 6, 2026
$1,001.00–$15,000.00